NCT06516926View on ClinicalTrials.gov

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions

HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Interventions

DRUG

SHR-4602

Intravenous infusion, cycle every 21 days;

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06516926 - SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter